Background and Objective: Development of appropriate translational in vivo models is a prerequisite for personalized management of leukemic patients. Indeed, several immunodeficient mice models were developed for leukemias with main limitations due to their high cost, demanding management, and elongated assessment intervals. In this report, we aimed at evaluating the engraftment of CD34 + cells, isolated from an acute myeloid leukemia (AML) patient, in naturally immunodeficient chick embryo model.
Introduction
Despite the significant advances in our understanding of acute myeloid leukemia (AML) pathogenesis, outcomes and 5-years overall survival of AML patients remain poor, with relapse commonly observed after remission [1] . This could be largely explained by insufficient eradication of a subpopulation of leukemic cells called leukemic stem cells (LSCs) . LSCs, which have been shown to be primarily in the CD34 + population, are found in a quiescent state the majority of time and thus are unlikely to respond to standard chemotherapeutic agents that tend to target actively cycling cells in tumor bulk [2, 3] . Therefore, identification of agents that target LSCs is a pivotal consideration for the development of new therapeutic strategies. For these therapies to become available, they must be first be tested in vitro, then in vivo in animal models, before clinical testing [1, 4] . Immunodeficient mice are the most current in vivo models used to study and manage hematological malignancies, with previous focus on severe combined immunodeficient (SCID) mice. However, the frequency of engrafted human cells was low in SCID mice. In an attempt to improve marrow engraftment efficiency, mice with greater immunodeficiency, such as Nonobese diabetic/SCID (NOD/SCID) and NOD/SCID IL2 receptor gamma chain knockout (NSG) mice, have been developed [5, 6] . Despite the obvious advantages obtained by developing these models, there are still some significant drawbacks. Namely, these models are expensive and require special costly maintenance conditions. In addition, engraftment of human cells requires at least one month. Therefore, new experimental cancer models have been described for preclinical drug testing [7, 8] .
Chick embryo has long been used in cancer research to study angiogenesis and metastasis and more recently, to evaluate the potential antitumor compounds in preclinical tests [9] [10] [11] [12] . This model has many advantages over immunocompromised murine models. It is inexpensive, naturally immunodeficient, requires no maintenance, and from a technical perspective, it is easily accessible for experimental manipulation. Moreover, human cells engraftment may occur within only one week. All these benefits, in addition to lack of pain and individual reaction to applied drugs that chick embryo reflects, suggest this model to be used in rapid drug screening and in personalized testing of therapeutics [7, 8, 13] .
For individualized drug testing to be performed, engraftment of primary cells from every single patient might be considered. In our study, we report engraftment of primary CD34 + AML cells into several chick embryo organs. Engraftment was detected by RT-PCR, with cell proliferation within the chick embryo system evaluated by in vitro culture.
Materials and methods

Primary cells preparation
Peripheral blood (PB) sample from a newly diagnosed AML M1 patient was obtained after informed consent, following procedures approved by the Institutional Ethical Committee. Mononuclear cells (MNCs) were isolated from the sample using Ficoll-Paque TM PLUS density gradient separation (STEMCELL Technologies, Canada). Positive selection of CD34 + cells was applied using immunomagnetic cell isolation EasySep TM kit (STEMCELL Technologies, Canada) according to the manufacturer's instructions. Purity of selected cells was measured by flow cytometry (FACSCalibur TM , BD Biosciences, USA). Cells were stained with FITC-conjugated anti-CD34 antibody (Abcam, UK), and data analysis was performed using CellQuest Pro software (BD Biosciences, USA).
Eggs preparation and primary AML cells IV injection into embryos
Fertilized chicken eggs were acquired from local farms and incubated in a rotating incubator for 11 days at 100°F and 60% humidity. On developmental day 11, the large chorioallantoic membrane (CAM) vein was marked and a small window was created in the eggshell above the vein. 5 Â 10 4 or 2 Â 10 4 of MNCs or 2 Â 10 4 of CD34 + cells, suspended in 100 ml PBS, were injected into the CAM vein and the window was sealed with a piece of laboratory tape and eggs returned to the incubator. 3 days before hatching (E18), chick embryos were sacrificed using protocols approved by the Institutional Ethical Committee. For analysis and detection of human cells, PB was collected from embryos injected with human MNCs. Bone marrow (BM), spleen and liver were collected from embryos injected with human CD34 + cells. We used
Ficoll enriched MNCs to get rid of as much as possible of chick embryo nucleated erythrocytes found in PB and BM.
RT-PCR analysis
Total RNA was extracted from fresh MNCs and tissues using Trizol (TRI Reagent Ò , Sigma, USA) according to the manufacturer's recommendations. mRNA was reverse transcribed into cDNA using oligo dT primers and RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, USA). PCR reactions were performed using Quick-Load Ò Taq 2X Master Mix (New England Biolabs, USA) and primers specific to human CD34 transcript (For primer 5-CAACACGTGGTGGCTGATAC-3 and Rev primer 5-AAGGGTTGGGCGTAAGAGAT-3). Primers and predicted PCR product of CD34 transcript (138bp) sequences were tested via BLAST tool and MFEprimer-2.0 program to confirm specificity to Homo Sapiens. PCR reaction program was set to the following conditions; denaturation at 95°C, 30 s, annealing at 55°C, 30 s and extension at 68°C, 1 min, and PCR performed using One-Personal thermocycler (EuroClone, Italy) for 35 cycles. cDNAs of blood samples were amplified with two rounds of PCR, each includes 25 cycles. Human AML cells served as positive control and PBS injected chick embryos served as negative control.
Peripheral blood mononuclear cells (PBMCs) culture and immunofluorescence phenotyping
Part of PBMCs isolated from blood of chick embryos injected with human AML MNCs or PBS (negative control) were cultured in RPMI supplemented with 20% FBS at 37°C in a humidified atmosphere containing 5% CO 2 . After 2 weeks, smears of cultured cells were prepared for detection by immunofluorescence microscopy. Cells were stained with FITC-conjugated anti-CD34 antibody (Abcam, UK) and nuclei stained with DAPI.
Histological analysis
Spleens and livers from PBS or human CD34
+ cells injected chick embryos were fixed in 10% neutral buffered formalin for 24 h. After that, tissues were dehydrated in a graded ethanol series, cleared with xylene and embedded in paraffin wax. Tissues were then cut using the microtome at 5 mm thickness and stained with hematoxylin and eosin.
Results
Flow cytometry of AML MNCs and purified CD34 + cells
Initial flow cytometry analysis of AML patient MNCs revealed that only 12.3% of MNCs were CD34 + . Next, CD34 + cells were enriched using immunomagnetic approach. The purity of CD34 + cells was >85% after selection ( Fig. 1) , whereas cell viability was always above 80%.
Expression of human CD34 in the blood of embryos injected with AML MNCs
Intravenous administration of 5 Â 10 4 AML MNCs resulted in the death of embryos in 100% of cases. When 2 Â 10 4 MNCs were injected, most of embryos survived. Expression of human CD34 in PB of embryos was assessed by RT-PCR using primers specific to human CD34 transcript. Bioinformatics analysis confirmed the specificity of the primers to human, as no potential amplicons were found in chicken genome and transcripts databases. Expression of human CD34 was not detectable after 35 amplification cycles. It was only detected after two rounds of PCR; 25 cycles per round, resulting in the appearance of weak intensity PCR bands (Fig. 2) .
Proliferation capacity of human cells
To estimate proliferative capacity of human CD34 + cells in culture, PBMCs isolated from embryos injected with human AML MNCs or PBS were cultured in vitro. After few days, colonies of cells started to appear in some of the wells belonged only to embryos receiving the human AML cells. The most exciting observation was after 14 days of culture when large foci of grouped cells were observed. The proliferated cells were densely packed in an envelope-like that separated them from other cells in the well (Fig. 3a and b) . To confirm the human origin and the CD34 + profile of these proliferative cells, smears from these cells were prepared
